Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Overall, 684 (77.4%) patients harbored gene alterations, and <i>EGFR </i> (510, 57.7%) was found to be the most common type of mutation followed by <i>KRAS </i> (91, 10.3%), <i>HER2 </i> (38, 4.3%), <i>PIK3CA </i> (32, 3.6%), <i>ALK </i> (21, 2.4%), <i>BRAF </i> (10, 1.1%), <i>ROS1 </i> (5, 0.6%), <i>RET </i> (5, 0.6%), <i>MET </i> (4, 0.5%) and <i>NRAS </i> (1, 0.1%) Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (<i>P </i> < 0.001). <i>EGFR </i> mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma <i>(P </i> < 0.001). Patients without lymph node metastasis (<i>P </i> = 0.012), or early stage disease (<i>P </i> < 0.001) exhibited a higher <i>EGFR </i> mutation rate. <i>KRAS </i> mutations tended to arise in men (<i>P </i> < 0.001), smokers (<i>P </i> < 0.001) and patients with higher levels of serum tumor markers (<i>P </i> = 0.048). A mucus‐producing component was associated with <i>KRAS </i> (<i>P </i> < 0.001), <i>ROS1 </i> (<i>P </i> = 0.033) and <i>ALK </i> (<i>P </i> < 0.001) alterations. <i>ALK </i> and <i>ROS1 </i> rearrangements were more frequent in micropapillary structures (<i>P </i> = 0.004, <i>P </i> = 0.012). <i>BRAF </i> mutation was associated with advanced disease patients and micropapillary structure (<i>P </i> < 0.001). <i>PIK3CA </i> mutation was more likely to be found in elderly patients (<i>P </i> = 0.014). Some patients had synchronous gene alterations, including <i>EGFR/PIK3CA </i>, <i>EGFR/HER2 </i>, <i>HER2/KRAS </i>, <i>EGFR/KRAS </i>, <i>EGFR/ROS1 </i>, <i>EGFR/NRAS </i>, <i>KRAS/PIK3CA </i>, <i>KRAS/PIK3CA/HER2. </i></p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS).</p></section>

Genomic Characteristics of Driver Genes in Chinese Patients with Non‐small Cell Lung Cancer

Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

Identification Of Enriched Driver Gene Alterations In Subgroups Of Non-Small Cell Lung Cancer Patients Based On Histology And Smoking Status

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Driver Gene Alterations Profiling of Chinese Non‐small Cell Lung Cancer and the Effects of Co‐occurring Alterations on Immunotherapy

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules

P3.02-040 Driver Gene Detection in Chinese NSCLC Patients Using Csmart and Prognosis Analysis

Expression Profiling of Driver Genes in Female Never-smokers with Non-adenocarcinoma Non–small-cell Lung Cancer in China

Incidence of Inconsistent Driver Mutations Between Multiple Lung Ground-Glass Nodules in Patients with Non-Small Cell Lung Cancer

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

Pathogenic Germline Mutation Profile In Chinese Lung Cancers And Related-Driver Mutation Pattern.

Association Between Certain Non–small Cell Lung Cancer Driver Mutations and Predictive Markers for Chemotherapy or Programmed Death‐ligand 1 Inhibition

Characterization of Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients Using a Novel Targeted Sequencing Panel

Clinical Characteristics Associated with Metastatic Nsclc Harboring Alk Rearrangements in Chinese Patients.

Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations